Study Summary
This trialis testing a drug for people with advanced cancer to see if it's safe and effective.
- Breast Cancer
- Colon Cancer
- Tumors
- Soft Tissue Sarcoma
- Pancreatic Cancer
- Solid Tumors
- Colorectal Cancer
- Ovarian Cancer
- Endometrial Cancer
Treatment Effectiveness
Effectiveness Progress
Study Objectives
1 Primary · 12 Secondary · Reporting Duration: Baseline to study completion (estimated up to 4 years)
Trial Safety
Safety Progress
Trial Design
10 Treatment Groups
Part A: LY2880070
1 of 10
Part A: LY2880070 with Gemcitabine
1 of 10
Part B:LY2880070 and Gemcitabine (Ovarian)
1 of 10
Part B: LY2880070 and Gemcitabine (Endometrial)
1 of 10
Part B: LY2880070 and Gemcitabine (Soft Tissue Sarcoma (STS))
1 of 10
Part C: LY2880070 and Gemcitabine (High Grade Serous Ovarian Cancer)
1 of 10
Part A: LY2880070 (Metabolism Phenotype)
1 of 10
Part B: LY2880070 and Gemcitabine (Colorectal)
1 of 10
Part B: LY2880070 and Gemcitabine (Pancreatic)
1 of 10
Part B: LY2880070 and Gemcitabine (Breast)
1 of 10
Experimental Treatment
229 Total Participants · 10 Treatment Groups
Primary Treatment: Part A: LY2880070 · No Placebo Group · Phase 1 & 2
Trial Logistics
Trial Timeline
Who is running the clinical trial?
Eligibility Criteria
Age 18+ · All Participants · 8 Total Inclusion Criteria
Mark “Yes” if the following statements are true for you:Frequently Asked Questions
Are there multiple venues in Canada where this research project is being conducted?
"This ongoing medical trial is available at 9 locations, including Montreal, Edmonton and Detroit. It would be prudent to choose the nearest study site so as to limit your transportation burden should you decide to join." - Anonymous Online Contributor
Does this experiment still accept volunteers?
"That is correct. According to clinicaltrials.gov, the trial which was originally posted on May 16th 2016 has recently resumed recruiting efforts and seeks 229 patients from 9 different locations." - Anonymous Online Contributor
To which maladies is Part B: LY2880070 and Gemcitabine (Soft Tissue Sarcoma (STS)) commonly deployed?
"Part B: LY2880070 and Gemcitabine (Soft Tissue Sarcoma (STS)) are indicated for use in small cell lung cancer treatment, but may also be useful to treat other carcinomas such as head and neck cancers, pancreatic adenocarcinoma locally advanced, or cervical tumours." - Anonymous Online Contributor
What is the maximum capacity for enrollment in this research project?
"Correct. According to clinicaltrials.gov, this study has been recruiting since May 16th 2016 and was last updated on January 11th 2023. The protocol requires the enrolment of 229 participants from 9 different medical sites." - Anonymous Online Contributor
Are there any other research projects that have tested the efficacy of Part B: LY2880070 and Gemcitabine when treating Soft Tissue Sarcoma (STS)?
"Currently, 416 trials assessing the efficacy of Part B: LY2880070 and Gemcitabine (Soft Tissue Sarcoma (STS)) are in progress with 127 at Phase 3. While Adelaide, South Australia has the most studies devoted to this research endeavor, there remain 23323 clinical trial sites around the world investigating Part B: LY2880070 and Gemcitabine (Soft Tissue Sarcoma (STS))." - Anonymous Online Contributor